Mitotane

米托坦

Report date: 2023/09/20 16:21:15
NME

Base Information

Drug NameMitotane
Drug Alias Namep'-DDDMitotanoMitotanumLysodrenNSC-38721 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSteroid hormone receptor antagonists
TargetsSteroid hormone receptor
Therapy Area/IndicationsProstatic NeoplasmsAdrenal Cortex NeoplasmsAdrenocortical Carcinoma
Global Approved IndicationsAdrenal Cortex NeoplasmsAdrenocortical Carcinoma
Approved Indications in ChinaAdrenocortical Carcinoma
Original Approved Country/TerritoryUnited States
Original Approved Date1970/07/08
Country/TerritoryMainland China(BOAO LECHENG)CanadaUnited States +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesEsteve Pharmaceuticals SaGiddi Pharma ( Shanghai ) Co LtdHra Pharma Rare Diseases
Inactive CompaniesUniversity Of TurinUniversity Health Network (Uhn)
Active IndicationsAdrenal Cortex NeoplasmsAdrenocortical Carcinoma
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeL01XX23
Related LinksWikipediaDrugBankKEGG